Drug Trial Radar · NCT06482437
Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
Last checked: Nov 19, 2026Latest source record: Nov 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Sep 30, 2024
Primary completion
Oct 28, 2025
Study completion Nov 4, 2025
Sponsor
- Lead sponsor
- NMD Pharma A/SIndustry
- Sponsor type
- Industry
- First posted
- Jul 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2a study aims to evaluate the efficacy, safety and tolerability of NMD670 vs placebo administered twice a day (BID) for 21 days in ambulatory adult patients with Charcot-Marie-Tooth disease type 1 and type 2.
Conditions
- Charcot-Marie-Tooth Disease
Interventions
NMD670Drug
Tablets taken twice daily for 21 days
PlaceboDrug
Tablets taken twice daily for 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to day 21 in 6-minute walk test total distance for NMD670 vs placeboTime frame: Baseline to day 21
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
University of Kansas Medical Center, Department of Neurology
Kansas City, Kansas
Mass General Neurology
Boston, Massachusetts
NextGen Precision Health
Columbia, Missouri
Columbia University Medical Center
New York, New York
University of Rochester Neuromuscular Disease Center
Rochester, New York
OSU Department of Neurology Division of Neuromuscular Diseases
Columbus, Ohio
National Neuromuscular research Institute, PLLC
Austin, Texas
Providence Medical Research Center
Spokane, Washington
University Hospitals Leuven, Department of Neurology
Leuven, Belgium
CHR de la Citadelle- Site Citadelle Neurolgie Boulevard du 12eme de Ligne 1
Liège, Belgium
Aarhus University Hospital
Aarhus, Denmark
Rigshospitalet, Department of Neurology
Copenhagen, Denmark
CHU Marseille, Reference centre for neuromuscular diseases and ALS Department of Neuromuscular Diseases
Marseille, France
Laboratoire d'Explorations Fonctionnelles, CHU Nantes
Nantes, France
Centre Hospitalier Universitaire De Nice
Nice, France
Institut de Myologie Groupe Hospitalier Pitié-Salpêtrière
Paris, France
Bicêtre University Hospital
Paris, France
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.